ocally Ablative Therapy for Oligo-Progressive, Oligo-Recurrent and Oligo-Persistent Non-Small Cell Lung Cancer â?? An Ambispective Observational Cohort study (OLIGO-CHROME)

Anil Tibdewal0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年4月3日

试验速览

阶段: 未知
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

入选标准

•1)Patients with histopathological diagnosis of non-small cell lung cancer
•2)Patients with age > 18 years
•3)Patients with confirmed oligoprogression in <=3 intracranial and extracranial sites of disease (excluding primary and regional nodal sites) - All sites must be visible, imaging defined targets, not previously treated with radical radiation or radiofrequency and suitable for treatment with LAT as determined by the radiation oncologist).
•4)Patients with oligoprogression in <=5 intracranial disease sites with no extracranial sites of progression. All sites must be visible, imaging defined targets, previous treatment of current sites with WBRT/SRS is acceptable with duration between treatment and OP is at-least 6 months.
•5)Patients with oligorecurrent disease at primary and/or regional nodal sites (previously covered in RT portal is allowed if can be treated radically again) with or without distant metastases in previously treated non-metastatic NSCLC.
•6)Patients with metastatic NSCLC with all sites responding to systemic therapy (TKI/Chemotherapy/ICI) except few (1-3) â?? Oligopersistent diseases
•7)Patient with completely resolved or stable pleural effusion is allowed but with no new onset malignant pleural or pericardial effusion
•8)All sites must be amenable either by local ablative radiation therapy (with SBRT/ Radical RT - conventional or hypofractionated RT) or RFA or Surgery
•9)At least one site should be treated with radiation therapy. Only RFA or Only Surgically treated patients will be excluded except patients with post-operative whole brain radiation therapy with or without boost or post-operative cavity stereotactic radiosurgery.
•10)Adequate baseline organ function to allow LAT to all the OP, OR or Oligopersistent targets.
•11)Karnofsky Performance status >= 60 and ECOG 0-2 (except patients with brain metastases where PS is declined solely due to brain s)
•12)Provision of written informed consent

排除标准

•1)Age < 18 years
•2) > 3 sites of oligoprogressive disease (except mentioned for intracranial sites only)
•3)OP, OR and oligopersistence disease not amenable to LAT
•4)Co-morbidities considered clinically precluding the safe use of LAT
•5)Any psychological, sociological or geographical issue potentially hampering compliance with the study
•6)Pregnancy

研究者

发起方

Anil Tibdewal

相似试验

进行中（未招募）

1 期

Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastasen.

EUCTR2022-000066-18-BEniversitaire Ziekenhuizen Leuven873

招募中

1 期

Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial treatment and a maximum of 5 metastases.Oligorecurrent hormone-sensitive prostate cancer patients

CTIS2022-502373-42-00Z Leuven873

招募中

1 期

Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANColigometastatic pancreatic cancer

CTIS2023-503558-10-00niversitaetsmedizin Goettingen425

尚未招募

不适用

Surgical treatment for oligoprogression in metastasized renal cell carcinoma after medical treatmentC64C78.0Malignant neoplasm of kidney, except renal pelvisSecondary malignant neoplasm of lung

DRKS00025088niversitätsklinikum Freiburg Klinik für Thoraxchirurgie20

招募中

1 期

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

CTIS2022-502254-13-00Z Leuven246